Company Disclosure
Kaya Limited (BSE: 539276, NSE: KAYA) announced its financial results for the quarter ended June 30, 2026, via a media release dated August 3, 2026.
Business Performance Update
Clinic Business Performance
- Clinic business registered 16% revenue growth over Q1 FY26
- Services business revenue growth of 16% driven by Brightening & Pigmentation, Acne & Scars, and Anti-Aging categories
- Skin business witnessed 19% growth over Q1 FY26
- Hair business showed 17% growth over Q1 FY26
Product Business Performance
- Product business registered 16% growth over Q1 FY26
- Growth mainly driven by Nutraceutical, Lighter and Brighter, and Anti-Aging categories
Financial Results
Revenue
- Revenue from operations: ₹60.1 crore for Q1 FY27
- Represents 14% growth over corresponding quarter Q1 FY26
Profitability
- Loss after tax: ₹(15.2) crore for Q1 FY27
- Compared to loss after tax of ₹(14.2) crore in Q1 FY26
- The higher loss was primarily driven by the impact of GST 2.0 changes effective September 2025, which restricted input tax credit availability
Company Background
Kaya Limited leads the aesthetic revolution in India with medical precision, ethical conviction, and disruptive innovation. The company has 20+ years legacy in aesthetic dermatology with:
- 600+ service lines
- 75+ product mix
- 100+ dermatologists
- 82 clinics pan-India